Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Conditions: Breast Cancer; Relapse; Resistant Cancer; Triple Negative Breast Cancer Interventions: Biological: iC9-CAR.B7-H3 T Cell Therapy; Drug: cyclophosphamide; Drug: fludarabine Sponsors: UNC Lineberger Comprehensive Cancer Center; Bellicum Pharmaceuticals Not yet recruiting

https://clinicaltrials.gov/study/NCT06347068

Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials

More News: Breast Cancer | Cancer | Cancer & Oncology | Research | Study